NCT04587427View on ClinicalTrials.gov

A Study to Learn More About How Radium-223 is Being Used With Other Treatments in European Patients Who Have Not Received Radium-223 Before

CompletedOBSERVATIONAL
Enrollment

1,067

Participants

Timeline

Start Date

May 15, 2021

Primary Completion Date

May 30, 2023

Study Completion Date

May 30, 2023

Conditions
Bone Metastatic Castration-resistant Prostate Cancer
Interventions
DRUG

Radium 223 dichloride (Xofigo, BAY88-8223)

Prescribed by physicians.

Trial Locations (3)

Unknown

Many Locations, Multiple Locations

Many Locations, Multiple Locations

Many Locations, Multiple Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT04587427 - A Study to Learn More About How Radium-223 is Being Used With Other Treatments in European Patients Who Have Not Received Radium-223 Before | Biotech Hunter | Biotech Hunter